➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Veliparib

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Veliparib?

Veliparib is an investigational drug.

There have been 92 clinical trials for Veliparib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Breast Neoplasms, Ovarian Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).

There are thirty US patents protecting this investigational drug and two hundred and one international patents.

Recent Clinical Trials for Veliparib
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerAbbViePhase 1
Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E MutationsNational Cancer Institute (NCI)Phase 2
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaNational Cancer Institute (NCI)Phase 2

See all Veliparib clinical trials

Clinical Trial Summary for Veliparib

Top disease conditions for Veliparib
Top clinical trial sponsors for Veliparib

See all Veliparib clinical trials

US Patents for Veliparib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Veliparib   Start Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
Veliparib   Start Trial System and method for diagnosis and treatment Pop Test Oncology Limited Liability Company (Cliffside Park, NJ)   Start Trial
Veliparib   Start Trial DNA2 inhibitors for cancer treatment City of Hope (Duarte, CA)   Start Trial
Veliparib   Start Trial Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (Bar Harbor, ME)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Veliparib

Drugname Country Document Number Estimated Expiration Related US Patent
Veliparib European Patent Office 3131552 2034-04-16   Start Trial
Veliparib Japan 2017514806 2034-04-16   Start Trial
Veliparib Japan 2019070012 2034-04-16   Start Trial
Veliparib New Zealand 629860 2034-04-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.